Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1Neoplasms 1Melanoma 1Adenocarcinoma 1

Interventions

Oxaliplatin 32Fluorouracil 24Gemcitabine 23Leucovorin 19Docetaxel 19pembrolizumab 17Capecitabine 15Radiotherapy 14Irinotecan 13Cisplatin 11Bevacizumab 11Nivolumab 8130-nm albumin-bound paclitaxel 8Trastuzumab 7Erlotinib Hydrochloride 7Cyclophosphamide 7Albumin-Bound Paclitaxel 7Radiosurgery 6Paclitaxel 6Taxes 5S 1 (combination) 5Metformin 5Carboplatin 5Blood Specimen Collection 5Sunitinib 4Sorafenib 4Pemetrexed 4Esophagectomy 4Chemoradiotherapy 4Cetuximab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Adenocarcinoma × LY3022855 × Clear all
NCT03153410 2025-01-09

Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase EARLY_PHASE1 Completed
11 enrolled 14 charts
Gastrointestinal

Adenocarcinoma, Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡